Jennifer Barrett, Assistant Editor

FDA grants accelerated approval for rucaparib (Rubraca) to treat advanced ovarian cancer.

Officials with Clovis Oncology announced today they have received accelerated FDA approval for Rubraca (rucaparib) to treat advanced ovarian cancers in women.

The FDA has issued a drug safety communication for young children and pregnant women regarding the use of general anesthetic and sedation drugs during surgeries or procedures.

The Institute for Safe Medication Practices works to identify the most prevalent medication safety issues and pinpoint effective strategies to reduce medication errors.

Pharmacists must be aware of medications associated with high risk for error and harm to patients.

It’s crucial for pharmacists to be aware of medications associated with high risk for error and harm to patients, and to look for best ways to implement practices for improving safety and patient care.

Health-system pharmacies can regulate cost-effective and efficient operations for parenteral nutrition compounding practices. Laura Mark, MS, PharmD, FASHP, led a tech talk at the Baxter Booth at the ASHP Midyear Clinical Meeting to discuss parenteral nutrition compounding practices.

Pharmacists are always looking to identify emerging trends that will inevitably have an impact on their practice and patient care.

Pharmacists are always looking to identify emerging trends that will inevitably have an impact on their practice and patient care.

Awards recognize best demonstrated practices and case studies designed to improve pharmacy processes, efficiency, and outcomes.

Misuse of antimicrobial agents has contributed to a growing number of infections impervious to antibiotic treatments.

Antibiotic resistance has become one of the most serious emerging threats to public health.

FDA approvea Relypsa, Inc.’s supplemental New Drug Application with label updates of Veltassa.

MDMA, better known as ecstasy or “Molly” and 3,4-methylenedioxymethamphetamine, is predominantly dismissed as an illicit street drug abused by raucous club-goers.

ASHP’s 2016 Midyear Clinical Meeting is the largest gathering of clinical pharmacists in the world.

The FDA has approved Relypsa, Inc.’s supplemental New Drug Application (sNDA) with label updates of Veltassa (patiromer) for oral suspension. Veltassa was approved by the FDA for the treatment of hyperkalemia on October 21, 2015.

Flu vaccinations during pregnancy do not seem to increase risk of autism spectrum disorders in children, according to a report published in JAMA Pediatrics.

A study that evaluated a phase 3 monoclonal antibody treatment that targeted Alzheimer’s disease, solanezumab (Eli Lilly), did not meet its primary endpoint in the EXPEDITION3 clinical trial, according to a statement from the company.

Expanded indication for FluLaval Quadrivalent includes use in children aged 6 months and older.

Officials with GlaxoSmithKline have received approval from the FDA’s Center for Biologics Evaluation and Research to expand the indication for FluLaval Quadrivalent to include use in children aged 6 months and older.

A historic clinical trial testing the efficacy of an experimental HIV vaccine regimen gets underway this week in South Africa.

The FDA has approved Sanofi’s once-daily Soliqua 100/33 (insulin glargine and lixisenatide injection) for the treatment of adults with type 2 diabetes.

The FDA has approved the new drug application for Novo Nordisk’s Xultophy 100/3.6 as an adjunct to diet and exercise in adults with type 2 diabetes.

Police reported 2 instances of pharmacy robberies involving a man and woman wielding hypodermic needles that they claimed were contaminated with HIV.

The FDA has announced a new research model that may expedite research and development for a Zika virus vaccine.

Although potential Zika virus vaccine candidates have shown promise in their early stages, emerging cases of the virus spreading throughout the United States have created urgency for the development of vaccination and therapeutic options.

The holidays are just around the corner, but that’s not the only exciting thing about this time of year. ASHP’s 2016 Midyear Clinical Meeting is coming up, and Pharmacy Times is on site covering it.

Guidelines revise the FDA regulations governing 505(b)(2) applications and abbreviated new drug applications.

Two pharmacists are being accused for their roles in a long-running, illegal prescription pain medication distribution conspiracy.

The FDA is issuing a final rule on generic drug applications, hoping to quicken the generic approvals process.